BACKGROUND: Real-world performance of COVID-19 diagnostic tests under Emergency Use Authorization (EUA) must be assessed. We describe overall trends in the performance of serology tests in the context of real-world implementation. METHODS: Six health systems estimated the odds of seropositivity and positive percent agreement (PPA) of serology test among people with confirmed SARS-CoV-2 infection by molecular test. In each dataset, we present the odds ratio and PPA, overall and by key clinical, demographic, and practice parameters. RESULTS: A total of 15,615 people were observed to have at least one serology test 14-90 days after a positive molecular test for SARS-CoV-2. We observed higher PPA in Hispanic (PPA range: 79-96%) compared to non-Hispanic (60-89%) patients; in those presenting with at least one COVID-19 related symptom (69-93%) as compared to no such symptoms (63-91%); and in inpatient (70-97%) and emergency department (93-99%) compared to outpatient (63-92%) settings across datasets. PPA was highest in those with diabetes (75-94%) and kidney disease (83-95%); and lowest in those with auto-immune conditions or who are immunocompromised (56-93%). The odds ratios (OR) for seropositivity were higher in Hispanics compared to non-Hispanics (OR range: 2.59-3.86), patients with diabetes (1.49-1.56), and obesity (1.63-2.23); and lower in those with immunocompromised or autoimmune conditions (0.25-0.70), as compared to those without those comorbidities. In a subset of three datasets with robust information on serology test name, seven tests were used, two of which were used in multiple settings and met the EUA requirement of PPA â¥87%. Tests performed similarly across datasets. CONCLUSION: Although the EUA requirement was not consistently met, more investigation is needed to understand how serology and molecular tests are used, including indication and protocol fidelity. Improved data interoperability of test and clinical/demographic data are needed to enable rapid assessment of the real-world performance of in vitro diagnostic tests.
Real-world performance of SARS-Cov-2 serology tests in the United States, 2020.
阅读：3
作者：Rodriguez-Watson Carla V, Louder Anthony M, Kabelac Carly, Frederick Christopher M, Sheils Natalie E, Eldridge Elizabeth H, Lin Nancy D, Pollock Benjamin D, Gatz Jennifer L, Grannis Shaun J, Vashisht Rohit, Ghauri Kanwal, Knepper Camille, Leonard Sandy, Embi Peter J, Jenkinson Garrett, Klesh Reyna, Garner Omai B, Patel Ayan, Dahm Lisa, Barin Aiden, Cooper Dan M, Andriola Tom, Byington Carrie L, Crews Bridgit O, Butte Atul J, Allen Jeff
| 期刊： | PLoS One | 影响因子： | 2.600 |
| 时间： | 2023 | 起止号： | 2023 Feb 3; 18(2):e0279956 |
| doi： | 10.1371/journal.pone.0279956 | ||
特别声明
1、本文转载旨在传播信息，不代表本网站观点，亦不对其内容的真实性承担责任。
2、其他媒体、网站或个人若从本网站转载使用，必须保留本网站注明的“来源”，并自行承担包括版权在内的相关法律责任。
3、如作者不希望本文被转载，或需洽谈转载稿费等事宜，请及时与本网站联系。
4、此外，如需投稿，也可通过邮箱info@biocloudy.com与我们取得联系。